Oculis Holding AG Ordinary Shares OCS 深 沪
等待开盘 12-03 09:30:00 美东时间
18.79
-0.210
-1.11%
华盛通- 最 高19.06
- 今 开19.06
- 成交量 9.43万股
- 最 低 18.64
- 昨 收 19.00
- 总市值 9.59亿
- 52周最高 23.08
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.00
- 委 比 -66.45%
- 总股本 5103.37万
- 历史最高 23.08
- 量 比 0.90
- 振 幅 2.21%
- 历史最低 6.26
- 每 手 1
- 风险率 1.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Needham Reiterates Buy on Oculis Holding, Maintains $36 Price Target
Needham analyst Serge Belanger reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $36 price target.
11-11 19:04
Oculis Holding Q3 EPS $(0.32) Beats $(0.50) Estimate, Sales $243.000K Miss $250.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.50) by 36 percent. This is a 41.82 percent increase over losses of $(0.55) per share from the
11-11 05:45
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Oculis Raises $110M Through Oversubscribed Offering To Advance Privosegtor Clinical Development And Strengthen Ophthalmology Pipeline
Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior
10-30 16:33
喜报！参投公司孛璞半导体中标硅光领域前沿项目
在人工智能浪潮席卷全球的今天，算力已然成为驱动产业智能化的核心引擎。 近日，上海孛璞半导体技术有限公司（以下简称“孛璞半导体”）成功中标上海市科委战略前沿专项项...
10-30 09:40
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
Oculis Holding AG announced the pricing of an aggregate of 5,432,298 ordinary shares at $20.25 per share, raising $110 million in gross proceeds. The company plans to use the funds to advance its Privosegtor candidate for treating acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, as well as for general corporate purposes. The offering includes 4,691,358 shares in an underwritten offering and 740,740 shares in a registered...
10-30 08:17
历史重现！十年首次！
早盘10：14分，A股迎来历史性一幕。 上证指数在银行、科技板块共同拉动下成功突破4000点大关，这是沪指历史第三次突破这一关键点位，也是其最近10年来首次站上...
10-28 17:58
TransMedics’ OCS Heart System: A Game Changer in Heart Transplantation?
Transmedics Group (($TMDX)) announced an update on their ongoing clinical study...
10-28 00:52
